Article
Medicine, General & Internal
Yuanjia Cheng, Hongyu Xiang, Ling Xin, Xuening Duan, Yinhua Liu
Summary: This study investigated the short-term clinical efficacy of neoadjuvant therapies trastuzumab and trastuzumab+pertuzumab for early HER2-positive breast cancer patients in China. It was found that patients in the trastuzumab+pertuzumab group had a higher pCR rate with tolerable toxic side effects compared to those in the trastuzumab group.
CHINESE MEDICAL JOURNAL
(2022)
Review
Oncology
Jane E. Rogers, Kohei Yamashita, Matheus Sewastjanow-Silva, Allison Trail, Rebecca E. Waters, Jaffer Ajani
Summary: Human epidermal growth factor receptor-2 (HER2) is a well-known cancer target with various therapies available. However, the response and effectiveness of HER2-targeted agents differ among different tumor types, including gastric adenocarcinomas (GACs). GACs exhibit heterogeneity in HER2 expression, both within and between tumors, which poses challenges in assessing the efficacy of HER2-targeted agents. The recent approval of trastuzumab deruxtecan, an antibody drug conjugate, for refractory HER2-positive advanced GAC patients shows promise. Ongoing research aims to understand resistance patterns and intra-tumor heterogeneity to improve treatment outcomes. This review discusses the current status of HER2-targeted therapy in GACs and explores new therapies under investigation.
Article
Oncology
Fangfang Duan, Muyi Zhong, Yuyu Ma, Chenge Song, Lehong Zhang, Ying Lin, Zhiyong Wu, Yuanqi Zhang, Jiajia Huang, Fei Xu, Yanxia Shi, Shusen Wang, Zhongyu Yuan, Wen Xia, Xiwen Bi
Summary: The switching mode showed superior efficacy compared to continuing mode in subsequent anti-HER2 therapy for patients with HER2-positive refractory metastatic breast cancer.
Article
Oncology
Preeti Narayan, Asma Dilawari, Christy Osgood, Zhou Feng, Erik Bloomquist, William F. Pierce, Samina Jafri, Shyam Kalavar, Marina Kondratovich, Prakash Jha, Soma Ghosh, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: The US FDA approved fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer. This is the first approved therapy specifically for HER2-low metastatic breast cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Laura A. Huppert, Ozge Gumusay, Dame Idossa, Hope S. Rugo
Summary: HR-positive/HER2-negative breast cancer is characterized by the presence of estrogen receptor and/or progesterone receptor and the absence of HER2 gene amplification. It accounts for a significant proportion of breast cancers and is treated with endocrine therapy. Combining endocrine therapy with cyclin-dependent kinase inhibitors has shown promising results in reducing recurrence and improving survival. Chemotherapy is used based on the stage and tumor biology. New therapies, such as novel endocrine agents and antibody-drug conjugates, are changing the treatment landscape.
CA-A CANCER JOURNAL FOR CLINICIANS
(2023)
Article
Oncology
Jens Huober, Carlos H. Barrios, Naoki Niikura, Michal Jarzab, Yuan-Ching Chang, Shannon L. Huggins-Puhalla, Jose Pedrini, Lyudmila Zhukova, Vilma Graupner, Daniel Eiger, Volkmar Henschel, Nino Gochitashvili, Chiara Lambertini, Eleonora Restuccia, Hong Zhang
Summary: This study investigated the efficacy of combining atezolizumab with chemotherapy in high-risk, HER2-positive early breast cancer patients. Results showed that atezolizumab did not increase pCR rates in either the ITT or PD-L1-positive populations, and more adverse events were seen in the atezolizumab group. Therefore, PH and chemotherapy remain the standard of care for these patients.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Ivica Ratosa, Nika Dobnikar, Michele Bottosso, Maria Vittoria Dieci, William Jacot, Stephane Pouderoux, Domen Ribnikar, Lea Sinoquet, Valentina Guarneri, Tanja Znidaric, Amelie Darlix, Gaia Griguolo
Summary: Leptomeningeal metastases (LM) in patients with HER2+ breast cancer are rare but often fatal. This multicentric study retrospectively gathered data from 82 patients with advanced HER2+ breast cancer and LM. The study found that absence of neurological symptoms and receiving radiotherapy were associated with prolonged overall survival.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Medicine, Research & Experimental
Rohit Sharma, Manoj Kumbhakar, Archana Mukherjee
Summary: Human epidermal growth factor receptor 2 (HER2) is overexpressed in various types of cancer, with combination therapy using trastuzumab and pertuzumab antibodies showing improved survival outcomes in breast cancer patients. Radiolabeled and fluorescently labeled antibodies were used in in vitro studies to investigate binding synergism in HER2 overexpressing cell lines. The results showed enhanced uptake of pertuzumab and its F(ab')(2) fragments when combined with trastuzumab, indicating synergism in their binding to HER2.
MOLECULAR PHARMACEUTICS
(2021)
Review
Oncology
Alessandro Rizzo, Antonio Cusmai, Raffaella Massafra, Samantha Bove, Maria Colomba Comes, Annarita Fanizzi, Gennaro Gadaleta-Caldarola, Donato Oreste, Alfredo Zito, Francesco Giotta, Vito Lorusso, Gennaro Palmiotti
Summary: This article provides a critical overview of current clinical recommendations and emerging treatment options for metastatic HER2-positive BC, with a focus on recently presented and published clinical trials in this setting.
Review
Oncology
Tresa M. McGranahan, Alipi Bonm, Jennifer M. Specht, Vyshak Venur, Simon S. Lo
Summary: This paper reviews the treatment options for patients with HER2+ breast cancer brain metastasis and provides a simplified algorithm for when to consider delaying local treatments.
Article
Medicine, Research & Experimental
Cancan Lyu, Yuanchao Ye, Maddison M. Lensing, Kay-Uwe Wagner, Ronald J. Weigel, Songhai Chen
Summary: In HER2(+) breast cancer, overactivation of HER2 leads to aberrant G(i/o)-GPCR signaling, promoting cancer progression and resistance to HER2-targeted therapy. Pharmacologically deactivating GPCR signaling can block tumor growth and enhance therapeutic efficacy.
Article
Pharmacology & Pharmacy
Lewis J. Renshall, Frances Beards, Angelos Evangelinos, Susan L. Greenwood, Paul Brownbill, Adam Stevens, Colin P. Sibley, John D. Aplin, Edward D. Johnstone, Tambet Teesalu, Lynda K. Harris
Summary: This study demonstrates the potential of using EGF-loaded, peptide-decorated liposomes to improve placental function. GPS-decorated liposomes containing EGF significantly increased amino acid transporter activity in healthy placental tissues, but were ineffective in those from pregnancies with FGR. Targeted liposomes represent a safe and useful tool for developing new therapies for placental dysfunction.
Article
Oncology
Huihui Yang, Wei Wang
Summary: This study compared the efficacy and safety of pyrotinib and lapatinib combined with chemotherapy in HER-2 positive breast cancer patients. The results showed that pyrotinib group had higher best objective response rate and longer progression free survival compared to lapatinib group, especially in patients with brain metastasis.
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
(2021)
Review
Oncology
Sonia Pernas, Sara M. Tolaney
Summary: The addition of trastuzumab to chemotherapy has significantly improved the prognosis of early-stage HER2-positive breast cancer, but disease recurrence still remains a challenge. Advances in understanding tumor biology have led to the development of optimized anti-HER2 drugs and strategies to further enhance survival outcomes. Recurrences in the brain, biological heterogeneity within HER2-positive disease, and the need to personalize treatment strategies based on biomarkers are key considerations in the management of early-stage, HER2-positive breast cancer.
JCO ONCOLOGY PRACTICE
(2021)
Article
Nanoscience & Nanotechnology
Lingzhou Zhao, Jiali Gong, Qinli Qi, Changcun Liu, Hongxing Su, Yan Xing, Jinhua Zhao
Summary: The unique structure of nanobodies is advantageous for the development of radiopharmaceuticals for nuclear medicine. In this study, a 131I-labeled anti-HER2 nanobody was generated and evaluated as a targeted radionuclide therapy agent for HER2-positive breast cancer. The results showed that 131I-NM-02 had satisfactory radiochemical purity and stability, and demonstrated good therapeutic potential and organ compatibility in HER2-positive tumors.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2023)
Article
Oncology
Anne Dyhl-Polk, Merete Vaage-Nilsen, Morten Schou, Kirsten Kjeldgaard Vistisen, Cecilia Margareta Lund, Thomas Kumler, Jon Michael Appel, Dorte Nielsen
Article
Anatomy & Morphology
Sofie S. Jespersen, Elisabeth S. Stovgaard, Dorte Nielsen, Troels D. Christensen, Anna S. K. Buhl, Ib J. Christensen, Eva Balslev
Summary: The study investigated the expression of sPLA2-IIa in breast cancer patients, finding a high proportion of patients with elevated levels of sPLA2-IIa expression, and similar expression levels in primary tumors and metastases. The expression of sPLA2-IIa showed no correlation with clinicopathologic characteristics and prognosis in the patients.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
(2021)
Article
Oncology
Anne Prip, Kathrine H. Pii, Dorte Lisbet Nielsen, Mary Jarden
Summary: This study aimed to explore patients' experiences of communication with healthcare professionals during their treatment in an oncology outpatient clinic and elucidate how their support needs are met. The results identified three categories of communication, namely verbal practices, relational practices, and nonverbal practices, which supported patients in managing their treatment and side effects. However, psychological, social, and existential concerns were rarely addressed.
Article
Oncology
Anne Dyhl-Polk, Morten Schou, Kirsten K. Vistisen, Anne-Sophie Sillesen, Eva Serup-Hansen, Jens Faber, Tobias W. Klausen, Stig E. Bojesen, Merete Vaage-Nilsen, Dorte L. Nielsen
Summary: Cardiotoxicity induced by 5-fluorouracil (5-FU) treatment is associated with an increased risk of myocardial ischemia, higher copeptin levels, but rare changes in cardiac troponin I. A small percentage of patients may develop acute coronary syndromes during treatment with 5-FU.
Article
Oncology
Mark T. J. van Bussel, Ahmad Awada, Maja J. A. de Jonge, Morten Mau-Sorensen, Dorte Nielsen, Patrick Schoffski, Henk M. W. Verheul, Barbara Sarholz, Karin Berghoff, Samer El Bawab, Mirjam Kuipers, Lars Damstrup, Ivan Diaz-Padilla, Jan H. M. Schellens
Summary: This phase 1 trial aimed to determine the maximum-tolerated dose and recommended phase 2 dose of peposertib, a DNA-dependent protein kinase inhibitor, in patients with advanced solid tumors. Peposertib was well-tolerated and showed modest efficacy in unselected tumors, with the recommended dose declared as 400 mg twice daily. Further studies are ongoing with peposertib/chemo-radiation combinations.
BRITISH JOURNAL OF CANCER
(2021)
Article
Cardiac & Cardiovascular Systems
Maria D'Souza, Dorte Nielsen, Inge Marie Svane, Kasper Iversen, Peter Vibe Rasmussen, Christian Madelaire, Emil Fosbol, Lars Kober, Finn Gustafsson, Charlotte Andersson, Gunnar Gislason, Christian Torp-Pedersen, Morten Schou
Summary: This study aimed to estimate the risk of cardiac events in lung cancer and malignant melanoma patients treated with immune checkpoint inhibitors. The results showed that patients treated with ICI had increased rates of cardiac events, with higher risks within 6 months of treatment initiation. After 6 months, the risks persisted in both patient groups.
EUROPEAN HEART JOURNAL
(2021)
Article
Oncology
Benny Vittrup Jensen, Jakob Schou, Mette Yilmaz, Helle H. Johannesen, Kristin Skougaard, Dorte Linnemann, Estrid Hogdall, Finn O. Larsen, Julia S. Johansen, Per Pfeiffer, Dorte L. Nielsen
Summary: This study investigated the use of cetuximab and irinotecan in third-line treatment for mCRC patients, regardless of RAS or BRAF mutation status, and achieved certain efficacy. Shortening the treatment time while maintaining good treatment outcomes.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Cecilia Margareta Lund, Anne Dyhl-Polk, Dorte Lisbeth Nielsen, Lene Buhl Riis
Summary: This study found no significant association between Wnt5a expression and prognosis in patients with stage II/III colon cancer. Patients with low Wnt5a expression had worse disease free survival and overall survival rates. Poor performance status was linked to lower DFS and OS.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Geriatrics & Gerontology
Troels G. Dolin, Marta Mikkelsen, Henrik L. Jakobsen, Tyge Nordentoft, Trine S. Pedersen, Anders Vinther, Bo Zerahn, Kirsten K. Vistisen, Charlotte Suetta, Dorte Nielsen, Julia S. Johansen, Cecilia M. Lund
Summary: This study aims to investigate the impact of CGA on physical performance in older frail patients undergoing surgery for CRC. The ongoing trial will provide valuable knowledge on whether preoperative CGA and postoperative geriatric follow-up and intervention including an exercise program can counteract physical decline and improve quality of life in frail CRC patients undergoing surgery.
Article
Oncology
Cecilia Margareta Lund, Kirsten Kjeldgaard Vistisen, Anne Pries Olsen, Pernille Bardal, Martin Schultz, Troels Gammeltoft Dolin, Finn Ronholt, Julia Sidenius Johansen, Dorte Lisbeth Nielsen
Summary: In the GERICO study, geriatric interventions compared with standard care increased the number of older, vulnerable patients with colorectal cancer completing adjuvant chemotherapy, and may improve the burden of illness and mobility.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Sidsel C. Lindgaard, Zsofia Sztupinszki, Emil Maag, Inna M. Chen, Astrid Z. Johansen, Benny Jensen, Stig E. Bojesen, Dorte L. Nielsen, Carsten P. Hansen, Jane P. Hasselby, Kaspar R. Nielsen, Zoltan Szallasi, Julia S. Johansen
Summary: A study identified two circulating protein indices with the potential to discriminate between individuals with and without PDAC.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Marta Kramer Mikkelsen, Hanne Michelsen, Dorte Lisbet Nielsen, Anders Vinther, Cecilia Margareta Lund, Mary Jarden
Summary: This study explored the experiences of older patients with advanced cancer who participated in a 12-week supervised and multimodal exercise program. Participants experienced several benefits, including physical improvements, increased energy, reduction of symptoms, and improved social engagement. However, pushing beyond physical limitations and experiencing severe symptoms were barriers towards exercising.
Article
Oncology
Marta K. Mikkelsen, Cecilia M. Lund, Anders Vinther, Anders Tolver, Julia S. Johansen, Inna Chen, Anne-Mette Ragle, Bo Zerahn, Lotte Engell-Noerregaard, Finn O. Larsen, Susann Theile, Dorte L. Nielsen, Mary Jarden
Summary: A 12-week multimodal exercise intervention including supervised exercise, protein supplement, home-based walking program, and nurse-led support proved effective in improving physical function in older patients with advanced cancer during oncological treatment. The study showed significant improvements in physical function, physical endurance, hand grip strength, physical activity, symptom burden, symptoms of depression and anxiety, global health status, and lean body mass. This highlights the importance of focusing on and supporting older patients with cancer in engaging in a physically active lifestyle and exercise training.
Review
Medicine, General & Internal
Anne Dyhl-Polk, Marta Kramer Mikkelsen, Morten Ladekarl, Dorte Lisbet Nielsen
Summary: This comprehensive review discusses the development of immune checkpoint inhibitors in hepatocellular carcinoma (HCC), highlighting the potential for durable tumor remission and manageable safety profiles. While monotherapy with CPIs did not meet prespecified endpoints in phase III trials, combining CPIs with other agents may offer new treatment options for patients with HCC. Research on predictive biomarkers is essential for further development of CPIs in HCC.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
R. L. Eefsen, K. S. Simonsen, P. Grundtvig, L. Klarskov, I. M. Chen, D. Hogdall, B. Jensen, T. Lorentzen, T. S. Poulsen, S. Theile, D. Nielsen, E. Hogdall
Summary: In this retrospective analysis, 90% of patients with treatment-refractory mCRC had cancer driver mutations identified through genomic sequencing, but only 2.5% of patients received targeted therapy that matched their mutations. The study highlights the challenge of limited targeted treatment options for mCRC patients with cancer driver mutations.
